Conference data: Phase III data support use of fenfluramine (Fintepla) in Dravet syndrome -

Conference data: Phase III data support use of fenfluramine (Fintepla) in Dravet syndrome
Information type: Media and commentaries
Source: DiabetesTeam
Specialities: Neurological disorders | Paediatric and neonatal medicine
Summary
Pooled RCT data (n=206) reported that fenfluramine, as an adjunctive treatment, reduced median baseline monthly frequency of generalized tonic-clonic seizures by 80%, 64%, and 48% in the fenfluramine 0.8, 0.5, 0.2 mg/kg/day groups, respectively, vs 10% in the placebo group.
UKMi comment
Fenfluramine is an investigational indirect-acting sympathomimetic which depresses rather than stimulates the CNS. It has been granted orphan drug designation by the European Medicines Agency for the treatment of seizures associated with Dravet Syndrome.
Related links: